Phase I trial of diaziquone (AZQ) plus GM-CSF

Lynn C. Hartmann; Matthew M. Ames; Joel M. Reid; Ronald L. Richardson

doi:10.1007/BF00872869

Phase I trial of diaziquone (AZQ) plus GM-CSF

Lynn C. Hartmann, Matthew M. Ames, Joel M. Reid, Ronald L. Richardson

Research output: Contribution to journal › Article › peer-review

Abstract

Diaziquone (AZQ) is a lipid soluble alkylating agent which was designed for increased CNS penetration. Its principle toxicity is myelosuppression. We conducted a phase I trial using AZQ in combination with GM-CSF to determine if the maximal tolerated dose (MTD) of AZQ could be escalated. Using GM-CSF on a standard schedule, we were unable to escalate the previously determined MTD of diaziquone with the use of this colony stimulating factor.

Original language	English (US)
Pages (from-to)	175-176
Number of pages	2
Journal	Investigational New Drugs
Volume	13
Issue number	2
DOIs	https://doi.org/10.1007/BF00872869
State	Published - Jun 1995

Keywords

AZQ
GM-CSF
diaziquone

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1007/BF00872869

Cite this

@article{8dcc6082ebaa4424978de6720e86e84c,

title = "Phase I trial of diaziquone (AZQ) plus GM-CSF",

abstract = "Diaziquone (AZQ) is a lipid soluble alkylating agent which was designed for increased CNS penetration. Its principle toxicity is myelosuppression. We conducted a phase I trial using AZQ in combination with GM-CSF to determine if the maximal tolerated dose (MTD) of AZQ could be escalated. Using GM-CSF on a standard schedule, we were unable to escalate the previously determined MTD of diaziquone with the use of this colony stimulating factor.",

keywords = "AZQ, GM-CSF, diaziquone",

author = "Hartmann, {Lynn C.} and Ames, {Matthew M.} and Reid, {Joel M.} and Richardson, {Ronald L.}",

year = "1995",

month = jun,

doi = "10.1007/BF00872869",

language = "English (US)",

volume = "13",

pages = "175--176",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "2",

}

TY - JOUR

T1 - Phase I trial of diaziquone (AZQ) plus GM-CSF

AU - Hartmann, Lynn C.

AU - Ames, Matthew M.

AU - Reid, Joel M.

AU - Richardson, Ronald L.

PY - 1995/6

Y1 - 1995/6

N2 - Diaziquone (AZQ) is a lipid soluble alkylating agent which was designed for increased CNS penetration. Its principle toxicity is myelosuppression. We conducted a phase I trial using AZQ in combination with GM-CSF to determine if the maximal tolerated dose (MTD) of AZQ could be escalated. Using GM-CSF on a standard schedule, we were unable to escalate the previously determined MTD of diaziquone with the use of this colony stimulating factor.

AB - Diaziquone (AZQ) is a lipid soluble alkylating agent which was designed for increased CNS penetration. Its principle toxicity is myelosuppression. We conducted a phase I trial using AZQ in combination with GM-CSF to determine if the maximal tolerated dose (MTD) of AZQ could be escalated. Using GM-CSF on a standard schedule, we were unable to escalate the previously determined MTD of diaziquone with the use of this colony stimulating factor.

KW - AZQ

KW - GM-CSF

KW - diaziquone

UR - http://www.scopus.com/inward/record.url?scp=0028886336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028886336&partnerID=8YFLogxK

U2 - 10.1007/BF00872869

DO - 10.1007/BF00872869

M3 - Article

C2 - 8617583

AN - SCOPUS:0028886336

SN - 0167-6997

VL - 13

SP - 175

EP - 176

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 2

ER -

Phase I trial of diaziquone (AZQ) plus GM-CSF

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this